REFERENCES
2. Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist 2010;15:994-1001.
3. Kalinsky K, Hershman DL. Cracking open window of opportunity trials. J Clin Oncol 2012;30:2573-5.
4. Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517:576-82.
5. Hoesli RC, Ludwig ML, Michmerhuizen NL, Rosko AJ, Spector ME, et al. Genomic sequencing and precision medicine in head and neck cancers. Eur J Surg Oncol 2017;43:884-92.
6. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333:1157-60.
7. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24:4170-6.
8. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
9. Schmitz S, Hamoir M, Reychler H, Magremanne M, Weynand B, et al. Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck. Ann Oncol 2013;24:2261-6.
10. Ferris RL, Kim S, Trivedi S, Srivastava RM, Concha-Benavente F, et al. Correlation of anti-tumor adaptive immunity with clinical response in a phase II "window" trial of neoadjuvant cetuximab in ptaients with resectable stage III-IV head and neck squamous carcinoma (HNSCC). J Clin Oncol 2016;34:6060.
11. Srivastava RM, Trivedi S, Concha-Benavente F, Hyun-Bae J, Wang L, et al. STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients. Cancer Immunol Res 2015;3:936-45.
12. Thomas F, Rochaix P, Benlyazid A, Sarini J, Rives M, et al. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clin Cancer Res 2007;13:7086-92.
13. Gross ND, Bauman JE, Gooding WE, Denq W, Thomas SM, et al. Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Clin Cancer Res 2014;20:3289-98.
14. Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, et al. Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. JCI Insight 2017;2:e90449.
15. Machiels JP, Bossi P, Menis J, Lia M, Fortpied C, et al. Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol 2018;29:985-91.
16. Uppaluri R, Winkler AE, Lin T, Law JH, Haughey BH, et al. Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial. Clin Cancer Res 2017;23:2186-94.
17. Day TA, Shirai K, O'Brien PE, Matheus MG, Godwin KB, et al. Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial. Clin Cancer Res 2019;25:1156-64.
19. Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J, Colevas AD, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016;375:1856-67.
20. Cohen EEW, Soulieres D, Le Tourneau C, Dinis J, Licitra L, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393:156-67.
21. Timar J, Ladanyi A, Forster-Horvath C, Lukits J, Dome B, et al. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial. J Clin Oncol 2005;23:3421-32.
22. Wolf GT, Fee WE, Jr., Dolan RW, Moyer JS, Kaplan MJ, et al. Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head Neck 2011;33:1666-74.
23. Berinstein NL, McNamara M, Nguyen A, Egan J, Wolf GT. Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen. Oncoimmunology 2018;7:e1423173.
24. Uppaluri R, Zolkind P, Lin T, Nussenbaum B, Jackson RS, et al. Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2017;35:6012.
25. Ferris RL, Goncalves A, Baxi SS, Martens UM, Gauthier H, et al. LBA46 - an open-label, multicohort, phase 1/2 study in patients with virus-associated cancers (CheckMate 358): safety and efficacy of neoadjuvant nivolumab in squamous cell carcinoma of the head and neck. Ann Oncol 2017;28:v605-v49.
26. Colevas AD, Bedi N, Chang S, Nieves UYM, Chatterjee S, et al. A study to evaluate immunological response to PD-1 inhibition in squamous cell carcinoma of the head and neck (SCCHN) using novel PET imaging with [18F]F-AraG. J Clin Oncol 2018;36:6050.
27. Bell RB, Duhen R, Leidner RS, Curti BD, Ballesteros-Merino C, et al. Neoadjuvant anti-OX40 (MEDI6469) prior to surgery in head and neck squamous cell carcinoma. J Clin ONcol 2018;36:6011.
28. Shayan G, Kansy BA, Gibson SP, Srivastava RM, Bryan JK, et al. Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. Clin Cancer Res 2018;24:62-72.
29. Rego DF, Pavan LM, Elias ST, De Luca Canto G, Guerra EN. Effects of metformin on head and neck cancer: a systematic review. Oral Oncol 2015;51:416-22.
30. Curry J, Johnson J, Tassone P, Vidal MD, Menezes DW, et al. Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial. Laryngoscope 2017;127:1808-15.
31. Schmitz S, Caballero C, Locati LD. Perspectives on window of opportunity trials in head and neck cancer: lessons from the EORTC 90111-24111-NOCI-HNCG study. Eur J Cancer 2018;104:219-23.
32. Spector ME, Farlow JL, Haring CT, Brenner JC, Birkeland AC. The potential for liquid biopsies in head and neck cancer. Discov Med 2018;25:251-7.
33. Baxi SS, Dunn LA, Burtness BA. Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma. Oral Oncol 2016;62:147-8.
34. Hanna GJ, Adkins DR, Zolkind P, Uppaluri R. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma. Oral Oncol 2017;73:65-9.
35. Saada-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2017;28:1605-11.
36. Schmitz S, Duhoux F, Machiels JP. Window of opportunity studies: Do they fulfil our expectations? Cancer Treat Rev 2016;43:50-7.
37. Primdahl H, Nielsen AL, Larsen S, Andersen E, Ipsen M, et al. Changes from 1992 to 2002 in the pretreatment delay for patients with squamous cell carcinoma of larynx or pharynx: a Danish nationwide survey from DAHANCA. Acta Oncol 2006;45:156-61.